UY35424A - Xantinas sustituidas y métodos para su uso - Google Patents
Xantinas sustituidas y métodos para su usoInfo
- Publication number
- UY35424A UY35424A UY0001035424A UY35424A UY35424A UY 35424 A UY35424 A UY 35424A UY 0001035424 A UY0001035424 A UY 0001035424A UY 35424 A UY35424 A UY 35424A UY 35424 A UY35424 A UY 35424A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- xantinas
- replaced
- trpc5
- inhibiting
- Prior art date
Links
- 102000003621 TRPC5 Human genes 0.000 abstract 2
- 101150042815 TRPC5 gene Proteins 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784448P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35424A true UY35424A (es) | 2014-10-31 |
Family
ID=50819943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035424A UY35424A (es) | 2013-03-14 | 2014-03-13 | Xantinas sustituidas y métodos para su uso |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140275528A1 (enExample) |
| EP (1) | EP2970316B1 (enExample) |
| JP (1) | JP2016513687A (enExample) |
| AR (1) | AR095561A1 (enExample) |
| TW (1) | TW201444844A (enExample) |
| UY (1) | UY35424A (enExample) |
| WO (1) | WO2014152287A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016023831A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
| WO2016086008A1 (en) * | 2014-11-26 | 2016-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Small molecule aldehyde dehydrogenase inhibitors and methods of use thereof |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| WO2018157800A1 (en) * | 2017-02-28 | 2018-09-07 | National Institute Of Biological Sciences, Beijing | Mlkl inhibitors |
| GB201712110D0 (en) * | 2017-07-27 | 2017-09-13 | Thomas Helledays Stiftelse För Medicinsk Forskning | New compounds and uses |
| CA3075727A1 (en) * | 2017-09-18 | 2019-03-21 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| US11623930B2 (en) | 2018-03-05 | 2023-04-11 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
| US20220152031A1 (en) * | 2019-03-20 | 2022-05-19 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| CN113603690B (zh) * | 2021-08-02 | 2022-10-25 | 南开大学 | 一种含黄嘌呤-8-基的(e)-丙烯酸衍生物及其制备方法和应用 |
| CN115636831B (zh) * | 2022-10-27 | 2024-11-08 | 中国药科大学 | 稠合嘧啶二酮类化合物、其用途以及药物组合物 |
| CN116023336A (zh) * | 2022-12-13 | 2023-04-28 | 河北医科大学 | 一种具有Nav1.7钠离子通道靶向抑制作用的化合物及其药物组合物和用途 |
| CN116217575B (zh) * | 2023-01-09 | 2025-01-10 | 广东赛烽医药科技有限公司 | 一种8-溴茶碱的制备方法 |
| CN118459461A (zh) * | 2023-02-08 | 2024-08-09 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090018148A1 (en) * | 2005-12-07 | 2009-01-15 | Ucb Pharma, S.A. | Xanthine Derivatives, Processes For Preparing Them And Their Uses |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
-
2014
- 2014-03-13 TW TW103108996A patent/TW201444844A/zh unknown
- 2014-03-13 UY UY0001035424A patent/UY35424A/es not_active Application Discontinuation
- 2014-03-14 WO PCT/US2014/027166 patent/WO2014152287A2/en not_active Ceased
- 2014-03-14 EP EP14726452.7A patent/EP2970316B1/en not_active Not-in-force
- 2014-03-14 US US14/210,666 patent/US20140275528A1/en not_active Abandoned
- 2014-03-14 JP JP2016502354A patent/JP2016513687A/ja not_active Withdrawn
- 2014-03-17 AR ARP140101183A patent/AR095561A1/es unknown
-
2016
- 2016-01-30 US US15/011,523 patent/US20160145257A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140275528A1 (en) | 2014-09-18 |
| AR095561A1 (es) | 2015-10-28 |
| WO2014152287A2 (en) | 2014-09-25 |
| EP2970316B1 (en) | 2017-11-08 |
| WO2014152287A4 (en) | 2015-02-19 |
| JP2016513687A (ja) | 2016-05-16 |
| EP2970316A2 (en) | 2016-01-20 |
| WO2014152287A9 (en) | 2015-04-23 |
| WO2014152287A3 (en) | 2014-12-04 |
| TW201444844A (zh) | 2014-12-01 |
| US20160145257A1 (en) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35488A (es) | Xantinas sustituidas y métodos para su uso | |
| UY35424A (es) | Xantinas sustituidas y métodos para su uso | |
| EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
| CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
| DK3596123T3 (da) | FC-optimeret anti-CD25 til tumorspecifik celledepletering | |
| EA201891211A1 (ru) | Ингибиторы cxcr2 | |
| CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| DOP2015000219A (es) | Compuestos de heteroarilo y sus usos | |
| CL2017000654A1 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| MX2015011514A (es) | Compuestos de heteroarilo y sus usos. | |
| MX380146B (es) | Inhibidores mk2 y usos de los mismos. | |
| BR112016008541A2 (pt) | composições úteis para tratar distúrbios relacionados a kit | |
| CR20150049A (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
| CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| CR20160419A (es) | Nuevos compuestos biciclicos | |
| DK2986726T3 (da) | Hidtil ukendte bacillusstammesammensætninger | |
| BR112015023310A2 (pt) | composições, métodos e kits para redução de níveis lipídicos | |
| EP3941635A4 (en) | SHREDDER | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| EP3584897A4 (en) | BREAKERS | |
| EP3702039C0 (en) | Crusher | |
| GT201300225A (es) | Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia | |
| DK3899996T3 (da) | Elektrolytsammensætninger | |
| DK3706710T3 (da) | Formuleringer med forlænget frigivelse til intraartikulære anvendelser | |
| IT201700040834A1 (it) | Composizioni comprendenti oli essenziali per uso topico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211112 |